First-pass effect is the liver’s metabolic processing of a drug right after it is absorbed from the gastrointestinal tract and before it reaches systemic circulation. When a drug is taken orally, it enters the intestinal wall and is carried via the portal vein directly to the liver, where enzymes can substantially reduce the amount of active drug that escapes into the bloodstream. That hepatic metabolism lowers the drug’s bioavailability and can even activate some prodrugs or inactivate others. Routes that bypass the liver, like intravenous administration, sublingual, or transdermal, avoid this initial first-pass step. The statement that defines the first-pass effect is that drugs absorbed from the GI tract enter the portal vein and pass through the liver before entering circulation. The other choices mischaracterize the process: first-pass doesn’t apply only to intravenous meds, it isn’t about bypassing the liver, and it doesn’t increase absorption in the stomach.

Morphine slows brain activity and breathing, so the most important safety rule is to avoid substances that add to this depressant effect. Alcohol and other CNS depressants (like sedatives or certain sleep medicines) can dramatically amplify sedation and respiratory depression, increasing the risk of severe drowsiness, slowed or stopped breathing, and even coma or death. That’s why this statement—avoiding alcohol and CNS depressants—is the best guidance for safe morphine use. Other options aren’t universal cautions. Morphine can often be taken with or without food unless a specific product says otherwise. While opioids can impair driving, the central, consistently important concept is to limit concurrent CNS depressants to prevent dangerous interactions, and respiratory distress should be treated as an urgent medical issue.

Haloperidol is a high-potency typical antipsychotic that strongly blocks dopamine D2 receptors in motor pathways. This blockade in the nigrostriatal system disrupts dopamine signaling enough to produce movement disorders known as extrapyramidal symptoms. EPS is a common and characteristic side effect with haloperidol, encompassing dystonia, akathisia, parkinsonism, and can progress to tardive dyskinesia with longer use. The other options—tachycardia, drowsiness, and photosensitivity—can occur with antipsychotics but do not reflect the motor side effects tied to haloperidol’s primary action.

Haloperidol is a typical antipsychotic because it acts mainly as a strong dopamine D2 receptor antagonist with little to no 5-HT2A receptor antagonism. This classic first-generation profile reduces positive psychotic symptoms but tends to produce extrapyramidal symptoms and hyperprolactinemia due to blocking D2 receptors in motor and tuberoinfundibular pathways. Atypical (second-generation) antipsychotics, by contrast, balance D2 blockade with significant 5-HT2A antagonism, which lowers EPS risk and often reduces prolactin elevation. Since haloperidol lacks notable serotonin receptor effects and has a high risk of motor side effects, it fits the category of typical antipsychotics.